Featured Article

BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews

Tomas Kirchhoff,1 Noah D. Kaufl,1 Nandita Mitra,2 Kedoudja Nafa,1 Helen Huang,1 Crystal Palmer,1 Tony Gulati,1 Eve Wadsworth,1 Sheri Donat,3 Mark E. Robson,1 Nathan A. Ellis,1 and Kenneth Offit1

1Clinical Genetics Service, Department of Medicine, 2Department of Epidemiology and Biostatistics, and 3Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York

Abstract

Purpose: The Breast Cancer Linkage Consortium and other family-based ascertenations have suggested that male carriers of BRCA mutations are at increased risk of prostate cancer. Several series looking at the frequency of BRCA mutations in unselected patients with prostate cancer have not confirmed this finding. To clarify this issue, we conducted a large case-control study.

Experimental Design: Blood specimens from 251 unselected Ashkenazi men with prostate cancer were screened for the presence of one of the three common Ashkenazi founder mutations in BRCA1 and BRCA2. The incidence of founder mutations was compared with the incidence of founder mutations in 1472 male Ashkenazi volunteers without prostate cancer using logistic regression analysis after adjusting for age.

Results: Thirteen (5.2%) cases had a deleterious mutation in BRCA1 or BRCA2 compared with 28 (1.9%) controls. After adjusting for age, the presence of a BRCA1 or BRCA2 mutation was associated with the development of prostate cancer (odds ratio, 3.41; 95% confidence interval, 1.64–7.06; P = 0.001). When results were stratified by gene, BRCA2 mutation carriers demonstrated an increased risk of prostate cancer (odds ratio, 4.78; 95% confidence interval, 1.87–12.25; P = 0.001), whereas the risk in BRCA1 mutation carriers was not significantly increased.

Conclusions: BRCA2 mutations are more likely to be found in unselected individuals with prostate cancer than age-matched controls. These results support the hypothesis that deleterious mutations in BRCA2 are associated with an increased risk of prostate cancer.

Introduction

Early reports from the Breast Cancer Linkage Consortium and other family-based ascertenations suggested that families with deleterious mutations in BRCA1 and BRCA2 had an increased number of prostate cancers compared with families without known inherited predisposition (1–5). Biological support for this association was provided by Gao et al. (6), who demonstrated loss of heterozygosity at the BRCA1 locus in hereditary prostate cancer cases. In an attempt to confirm these findings, several groups have looked at the incidence of deleterious BRCA1 and BRCA2 mutations in unselected series of patients with prostate cancer (7–11). The majority of these series have been performed in Ashkenazi populations because of the high frequency of three founder mutations in BRCA1 and BRCA2 in this group. Most series of unselected patients have concluded that deleterious BRCA mutations contribute little, if anything, to the incidence of prostate cancer in the Ashkenazi population. In the only series of unselected patients suggesting a weak association of BRCA mutations with prostate cancer risk, the effect was limited to BRCA1 mutation carriers (11). However, this finding was not confirmed in two recent family-based ascertainment limited to BRCA1 mutation carriers (12, 13). To better elucidate the impact of deleterious BRCA1 and BRCA2 mutations on prostate cancer risk, we conducted a large case-control study comparing the incidence of deleterious BRCA1 and BRCA2 founder mutations in unselected Ashkenazi prostate cancer patients and compared this with the frequency of BRCA1 and BRCA2 founder mutations in a well-characterized control population.

Patients and Methods

DNA was extracted from lymphocytes of blood specimens from 251 individuals of Ashkenazi Jewish ancestry diagnosed with adenocarcinoma of the prostate who received care at the outpatient urology clinic at Memorial Sloan-Kettering Cancer Center from April 2000 to September 2002. The samples were unselected for age or family history. Clinical and pathological records were reviewed to confirm the diagnosis of prostate cancer in all subjects. Once pathological diagnosis of prostate cancer was confirmed, the age of diagnosis was recorded, and all other identifying links were destroyed. The study design and anonymization method were approved by the Memorial Sloan-Kettering Cancer Center Institutional Review Board.

DNA from case samples was analyzed for the three common Ashkenazi founder mutations in BRCA1 and BRCA2 (185delAG and 5182insC in BRCA1 and 6174delT in BRCA2) as described previously (14). Briefly, DNA was purified using the QiaAmp Blood DNA midi kit (Qiagen, Valencia, CA). DNA specimens were then analyzed for the presence of the Ashkenazi founder mutations using the following oligonucleotide primers flanking the mutation loci: BRCA1, 185delAG forward (5’-
after adjusting for age by treating it as an additional covariate in
with controls was estimated using a logistic regression model,
files after excluding cases with a prior diagnosis of prostate
dergone genotyping for the three Ashkenazi founder mutations
Washington Ashkenazi Jewish Study who had previously un-
male volunteers without prostate cancer identified as part of the
previously verified
the comparison of test digest with digests of PCR analyses of
XI [6174delT (15)]. Carriers were recognized by
were computed for odds ratios. SAS version 8.2 (SAS
terminal. Fisher’s exact tests were conducted. Exact confidence in-
we were able to confirm that presence of a
presence of a
after the age of 60 years (odds ratio, 3.71; 95% confidence
possible that a survival bias in our series resulted from a
be due to the inclusion of only incident cases in the Israeli series,
we included both incident and prevalent cases. It is
of the 3.1% frequency seen in our series. This difference may
family-based ascertainments, one of the reasons that our results
for prostate cancer is consistent with predictions based on
way, we were able to confirm that presence of a
results were stratified by age, we were able to confirm that presence of a
mutations in prostate cancer cases (1.5%) was less than
prostate cancer risk, four series did not demonstrate an associ-
one population-based series observed a modest
elevation in prostate cancer risk (95% confidence interval, 1.05–
In the Ashkenazi Jewish population, the three founder
in BRCA1 and BRCA2 account for the vast majority of
inherited breast and ovarian cancer families (17, 18). Despite
evidence from several groups (2, 4) that prostate cancer was
overrepresented in hereditary breast cancer families linked to
BRCA2 (Table 2), no series of unselected Ashkenazi Jewish men
prostate cancer prior to the current series has been able to
confirm this association (Table 3). For BRCA1-linked kindreds,
the prior family-based series have shown either a higher (1),
lower (12), or average (13) risk of prostate cancer (Table 2).
In unselected series examining the impact of BRCA1 mutations on
prostate cancer risk, four series did not demonstrate an associ-
(7–10), and one population-based series observed a modest
increase in prostate cancer risk (95% confidence interval, 1.05–
Several studies have suggested that BRCA mutations are
predominately associated with an increased rate of early-onset
prostate cancer (13, 19, 20). When our results were stratified by
age, we were able to confirm that presence of a BRCA mutation
was associated with a significantly increased risk for prostate
after the age of 60 years (odds ratio, 3.71; 95% confidence
interval, 1.25–11.65; P = 0.01), but not for prostate cancer
before the age of 60 years (odds ratio, 3.03; 95% confidence
interval, 0.56–10.72; P = 0.10). However, this analysis was
limited by the very small number of men in the series (n = 3)
less than 60 years old with prostate cancer and a BRCA muta-
tion carriers. Four of these series were limited to fewer than
may differ from prior unselected series is that these studies were
not powered to discern different risks in BRCA1 versus BRCA2
mutation carriers. Four of these series were limited to fewer than
200 cases. In one large series from Israel, the frequency of
BRCA2 mutations in prostate cancer cases (1.5%) was less than
half the 3.1% frequency seen in our series. This difference may
be due to the inclusion of only incident cases in the Israeli series,
whereas we included both incident and prevalent cases. It is
possible that a survival bias in our series resulted from a BRCA2
mutation-associated survival advantage for patients with pro-
CATTAAATGCTATGCGAAAAAT) and 185delAG reverse (5’-
CTTACTAAGACATGTCCCTCC) and 5382insC forward
5382insC reverse (5’-GTTAGCTGCTCTGAAATGTTGTTA). PCR
products were analyzed by RFLP, using modified sites
(AGRES) for restriction enzymes Taq (185delAG), DdeI
(538insC), and BsrXI [6174delT (15)]. Carriers were recognized by
the comparison of test digest with digests of PCR analyses of
previously verified BRCA1/2 carriers.

We then compared the incidence of founder mutations in
cases with a control group that included 1472 Ashkenazi Jewish
male volunteers without prostate cancer identified as part of the
Washington Ashkenazi Jewish Study who had previously un-
dergone genotyping for the three Ashkenazi founder mutations
(3). The authors of this study kindly provided the primary data
files after excluding cases with a prior diagnosis of prostate
cancer. The odds ratio for prostate cancer in cases compared
with controls was estimated using a logistic regression model,
after adjusting for age by treating it as an additional covariate in
the model (16). For stratified analyses, χ² tests of association
and Fisher’s exact tests were conducted. Exact confidence in-
ervals were computed for odds ratios. SAS version 8.2 (SAS
Institute Inc., Cary, NC) was used for all analyses.

Results

Genotyping revealed that 13 of 251 cases (5%) were car-
riers of either a BRCA1 or BRCA2 mutation. Among the 13
carriers, 4 carriers had BRCA1 185delAG (1.6%), 1 carrier had
BRCA1 5382insC (0.4%), and 8 carriers had BRCA2 6174delT
(3.1%). Of the 1472 controls, 28 (1.9%) had either a
BRCA1 or BRCA2 mutation: 9 (0.6%) had
BRCA1 or BRCA2 mutation carriers. Four of these series were limited to fewer than
200 cases. In one large series from Israel, the frequency of
BRCA2 mutations in prostate cancer cases (1.5%) was less than
half the 3.1% frequency seen in our series. This difference may
be due to the inclusion of only incident cases in the Israeli series,
whereas we included both incident and prevalent cases. It is
possible that a survival bias in our series resulted from a BRCA2
mutation-associated survival advantage for patients with pros-
Table 1. Frequency of BRCA1 and BRCA2 mutations in cases and controls

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Cases (n = 251)</th>
<th>Controls (n = 1472)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (%)</td>
<td>Mean age of</td>
</tr>
<tr>
<td></td>
<td></td>
<td>mutation carriers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(range) (yrs)</td>
</tr>
<tr>
<td>BRCA1</td>
<td>5 (2.0%)</td>
<td>68.4 (65–71)</td>
</tr>
<tr>
<td>BRCA2</td>
<td>8 (3.2%)</td>
<td>64.0 (48–78)</td>
</tr>
<tr>
<td>BRCA1 or BRCA2</td>
<td>13 (5.2%)</td>
<td>65.7</td>
</tr>
</tbody>
</table>

* CI, confidence interval.

ratio, 2.20; 95% confidence interval, 0.72–6.70; P = 0.16; Table 1).

Discussion

In the Ashkenazi Jewish population, the three founder
mutations in BRCA1 and BRCA2 account for the vast majority of
inherited breast and ovarian cancer families (17, 18). Despite
evidence from several groups (2, 4) that prostate cancer was
overrepresented in hereditary breast cancer families linked to
BRCA2 (Table 2), no series of unselected Ashkenazi Jewish men
with prostate cancer prior to the current series has been able to
confirm this association (Table 3). For BRCA1-linked kindreds,
the prior family-based series have shown either a higher (1),
lower (12), or average (13) risk of prostate cancer (Table 2).
In unselected series examining the impact of BRCA1 mutations on
prostate cancer risk, four series did not demonstrate an associ-
(7–10), and one population-based series observed a modest
increase in prostate cancer risk (95% confidence interval, 1.05–
Several studies have suggested that BRCA mutations are
predominately associated with an increased rate of early-onset
prostate cancer (13, 19, 20). When our results were stratified by
age, we were able to confirm that presence of a BRCA mutation
was associated with a significantly increased risk for prostate
after the age of 60 years (odds ratio, 3.71; 95% confidence
interval, 1.25–11.65; P = 0.01), but not for prostate cancer
before the age of 60 years (odds ratio, 3.03; 95% confidence
interval, 0.56–10.72; P = 0.10). However, this analysis was
limited by the very small number of men in the series (n = 3)
less than 60 years old with prostate cancer and a BRCA muta-
tion carriers. Four of these series were limited to fewer than
200 cases. In one large series from Israel, the frequency of
BRCA2 mutations in prostate cancer cases (1.5%) was less than
half the 3.1% frequency seen in our series. This difference may
be due to the inclusion of only incident cases in the Israeli series,
whereas we included both incident and prevalent cases. It is
possible that a survival bias in our series resulted from a BRCA2
mutation-associated survival advantage for patients with pros-
tate cancer, leading to an over representation of the 6174delT allele in our largely prevalent cohort. Such an effect, as has been observed in BRCA-associated ovarian cancer (21–23), requires confirmation through prospective studies.

Another possible bias in our series could have occurred because the Washington Ashkenazi study was not population based but rather was composed of volunteers somewhat enriched for familial cancer history. If the frequency of founder mutations in unaffected individuals in the Washington Ashkenazi Study was different than the population frequency in Ashkenazi individuals in the greater New York area, this could have resulted in an over- or underestimation of the impact of BRCA mutations on prostate cancer risk. We believe this is unlikely because the founder mutation frequency seen in the Washington Ashkenazi Study is consistent with other large series of Ashkenazi individuals from both the greater New York area and other regions of the United States (24, 25).

Different methodologies were used for genotyping cases and controls. This theoretically could have introduced a bias in favor of a significant finding if the genotyping method for cases was more sensitive than the method used for controls. We believe this is unlikely, however, because the restriction site analysis used to genotype the cases and the allele-specific oligonucleotide assay used to genotype the controls have both been Table 3  Incidence of founder BRCA1 or BRCA2 mutations in unselected series of Jewish patients with prostate cancer

<table>
<thead>
<tr>
<th>Authors</th>
<th>N</th>
<th>Comparison group</th>
<th>Frequency of BRCA mutations in cases</th>
<th>Association of BRCA mutation and prostate cancer risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lehrer et al., 1998 (7)</td>
<td>60</td>
<td>268 Ashkenazi Jewish women with sporadic breast cancer</td>
<td>0 (0%) BRCA1 0 (0%) BRCA2</td>
<td>No</td>
</tr>
<tr>
<td>Nastiuk et al., 1999 (8)</td>
<td>83</td>
<td>Reported population incidence 1 (1.2%) BRCA1 2 (2.4%) BRCA2</td>
<td></td>
<td>No</td>
</tr>
<tr>
<td>Hubert et al., 1999 (9)</td>
<td>87</td>
<td>87 Ashkenazi Jewish men without prostate cancer 2 (2.3%) BRCA1 1 (1.1%) BRCA2</td>
<td></td>
<td>No</td>
</tr>
<tr>
<td>Vazina et al., 2000 (10)</td>
<td>174</td>
<td>Reported population incidence 4 (2.3%) BRCA1 1 (0.6%) BRCA2</td>
<td></td>
<td>No</td>
</tr>
<tr>
<td>Giusti et al., 2003 (11)</td>
<td>940</td>
<td>472 Ashkenazi Jewish men without prostate cancer 16 (1.7%) BRCA1 14 (1.5%) BRCA2</td>
<td></td>
<td>BRCA1-No  BRCA2-No</td>
</tr>
</tbody>
</table>

a Analysis limited to 185delAG mutation in BRCA1 and 6174delT mutation in BRCA2.

b When control population was combined with 872 controls from the United States, presence of the 185delAG mutation in BRCA1 was associated with an increased risk of prostate cancer. (odds ratio, 2.52; 95% confidence interval, 1.05–6.04).
shown in other studies to have a sensitivity for detecting the Ashkenazi founder mutations comparable with that of sequencing (22, 26, 27).

These results provide evidence that deleterious mutations in BRCA2 are associated with an increased risk of prostate cancer. Current recommendations for male carriers of BRCA mutations include prostate cancer screening with digital rectal examination and serum prostate-specific antigen level annually beginning at age 50 years (28). Whereas there was no significantly increased risk for early-onset prostate cancer in this series, this finding requires confirmation in a larger cohort. Additional family-based studies may also help clarify the relative penetrance of BRCA2 mutations for prostate cancer. Additionally, because a substantial proportion of familial prostate cancer is not linked to mutations in BRCA1 and BRCA2, the search for other major prostate cancer predisposition genes will remain a high priority.

Acknowledgments

We are grateful to the Washington Ashkenazi Study Investigators, including Drs. Jeffrey P. Struwing, Patricia Hartge, Shalom Wacholder, Lawrence C. Brody, and Margaret A. Tucker, who kindly provided the raw data files, including the age- and gender-specific rates needed for the analyses in this study.

References

BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews


Updated version  Access the most recent version of this article at: 
http://clincancerres.aacrjournals.org/content/10/9/2918

Cited articles  This article cites 24 articles, 7 of which you can access for free at: 
http://clincancerres.aacrjournals.org/content/10/9/2918.full#ref-list-1

Citing articles  This article has been cited by 15 HighWire-hosted articles. Access the articles at: 
http://clincancerres.aacrjournals.org/content/10/9/2918.full#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link 
http://clincancerres.aacrjournals.org/content/10/9/2918.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.